Cipla Limited - Asset Resilience Ratio
Cipla Limited (CIPLA) has an Asset Resilience Ratio of 20.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cipla Limited strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Cipla Limited's Asset Resilience Ratio has changed over time. See Cipla Limited net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cipla Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CIPLA stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs7.96 Billion | 1.98% |
| Short-term Investments | Rs75.39 Billion | 18.77% |
| Total Liquid Assets | Rs83.35 Billion | 20.75% |
Asset Resilience Insights
- Good Liquidity Position: Cipla Limited maintains a healthy 20.75% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cipla Limited Industry Peers by Asset Resilience Ratio
Compare Cipla Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Cipla Limited (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Cipla Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 26.83% | Rs100.32 Billion ≈ $1.08 Billion |
Rs373.87 Billion ≈ $4.04 Billion |
+4.93pp |
| 2024-03-31 | 21.90% | Rs71.65 Billion ≈ $774.91 Million |
Rs327.18 Billion ≈ $3.54 Billion |
+2.49pp |
| 2023-03-31 | 19.41% | Rs57.19 Billion ≈ $618.51 Million |
Rs294.63 Billion ≈ $3.19 Billion |
+4.58pp |
| 2022-03-31 | 14.83% | Rs40.19 Billion ≈ $434.67 Million |
Rs271.01 Billion ≈ $2.93 Billion |
+2.49pp |
| 2021-03-31 | 12.34% | Rs31.03 Billion ≈ $335.55 Million |
Rs251.52 Billion ≈ $2.72 Billion |
+10.48pp |
| 2020-03-31 | 1.86% | Rs4.39 Billion ≈ $47.52 Million |
Rs236.63 Billion ≈ $2.56 Billion |
+1.32pp |
| 2019-03-31 | 0.53% | Rs1.28 Billion ≈ $13.86 Million |
Rs239.63 Billion ≈ $2.59 Billion |
-0.07pp |
| 2018-03-31 | 0.61% | Rs1.39 Billion ≈ $15.05 Million |
Rs228.61 Billion ≈ $2.47 Billion |
+0.55pp |
| 2017-03-31 | 0.06% | Rs118.30 Million ≈ $1.28 Million |
Rs210.37 Billion ≈ $2.28 Billion |
-2.71pp |
| 2016-03-31 | 2.77% | Rs5.85 Billion ≈ $63.26 Million |
Rs211.28 Billion ≈ $2.28 Billion |
+0.29pp |
| 2015-03-31 | 2.48% | Rs3.90 Billion ≈ $42.18 Million |
Rs157.18 Billion ≈ $1.70 Billion |
-0.43pp |
| 2014-03-31 | 2.91% | Rs3.90 Billion ≈ $42.18 Million |
Rs134.03 Billion ≈ $1.45 Billion |
-15.25pp |
| 2013-03-31 | 18.16% | Rs21.17 Billion ≈ $228.92 Million |
Rs116.59 Billion ≈ $1.26 Billion |
+8.10pp |
| 2012-03-31 | 10.06% | Rs9.41 Billion ≈ $101.71 Million |
Rs93.50 Billion ≈ $1.01 Billion |
+7.46pp |
| 2011-03-31 | 2.60% | Rs2.24 Billion ≈ $24.18 Million |
Rs85.97 Billion ≈ $929.70 Million |
+2.59pp |
| 2010-03-31 | 0.01% | Rs5.20 Million ≈ $56.24K |
Rs73.09 Billion ≈ $790.45 Million |
-13.04pp |
| 2009-03-31 | 13.05% | Rs8.95 Billion ≈ $96.78 Million |
Rs68.57 Billion ≈ $741.53 Million |
-6.20pp |
| 2008-03-31 | 19.25% | Rs11.03 Billion ≈ $119.33 Million |
Rs57.33 Billion ≈ $619.96 Million |
+4.05pp |
| 2007-03-31 | 15.20% | Rs6.71 Billion ≈ $72.56 Million |
Rs44.14 Billion ≈ $477.33 Million |
+3.59pp |
| 2006-03-31 | 11.61% | Rs4.01 Billion ≈ $43.42 Million |
Rs34.58 Billion ≈ $374.01 Million |
-3.36pp |
| 2005-03-31 | 14.97% | Rs3.91 Billion ≈ $42.28 Million |
Rs26.12 Billion ≈ $282.50 Million |
-0.43pp |
| 2004-03-31 | 15.40% | Rs3.42 Billion ≈ $36.98 Million |
Rs22.20 Billion ≈ $240.10 Million |
-- |
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more